Michael J. Miller, RPh, DrPH, FAPhA

Michael Miller
Research Scientist II
(301) 816-7260
Michael.J1.Miller@kp.org

Professional affiliations:

Academy of Health Services Research
American Pharmacists Association
American Society of Health System Pharmacy

Education:

2004 – Doctor of Public Health, Graduate School of Public Health, University of Pittsburgh
1995 – Master of Science in Pharmacy Administration, College of Pharmacy, The University of Arizona
1988 – Bachelor of Science Degree in Pharmacy, School of Pharmacy, University of Pittsburgh

 

Dr. Miller has been a pharmacist for more than 30 years in clinical, management and research environments across private, government and academic sectors. He holds Bachelor and Master of Science degrees in pharmacy, a Doctor of Public Health degree, and is a Fellow of the American Pharmacists Association. He has taught courses related to design, analysis and interpretation of research studies to ensure appropriate application to healthcare decision-making in professional and graduate programs. Most recently at Texas A&M University, he taught content related to the US health care system and the social and behavioral aspects of the medication use process. Using both primary and secondary data, he has focused study on refining methods to measure and identify those at risk for low health literacy, evaluating the literacy-sensitivity of pharmacy processes and environments, and identifying interventions that improve health literacy and ensure optimal medication use and risk communication.

He has served as a Special Government Employee (SGE) Consultant to the FDA/CDER Advisory Committee for Pharmaceutical Science and Clinical Pharmacology. His primary areas of clinical interest include cardiovascular-related disease, rheumatology, depression, and infectious disease. Past and present external partners for his research initiatives include the Iowa Health System, the American Society of Health System Pharmacists Research and Education Foundation, the University of Alabama – Birmingham Deep South Arthritis and Musculoskeletal Center for Education and Research on Therapeutics (DSAM CERTs), and First Databank.

 

For a full list of publications, please see Dr. Miller’s Curriculum Vitae

 

  1. Miller M, Watson E, Horberg M, Bhatia M, Tripuranen B, McCarthy R, “Patient Experience After Modifying Visit Delivery During the COVID-19 Pandemic” The American Journal of Managed Care. Accepted November 23, 2020.
    Abstract
  2. Miller M, Joub T, Danilac M, Mudanod A, Rahne E, Outmanf R, Saagg K, “Use of path modeling to inform a clinical decision support application to encourage osteoporosis medication use,” Research in Social and Administrative Pharmacy. 2020
    Abstract
  3. Adami G, Saag K, Mudano A, Rahn E, Wright N, Outman R, Greenspan S, LaCroix A, Nieves J, Silverman S, Siris E, Watts N, Miller M, Ladores S, Curtis J, Danila M. “Factors associated with the contemplative stage of readiness to initiate osteoporosis treatment.” Osteoporosis International. 2020. Available online February 4, 2020.
    Abstract
  4. Desselle S, Chen A, Amin M, Aslani P, Dawoud D, Miller M, Nørgaard L. “Generosity, collegiality, and scientific accuracy when writing and reviewing original research.” Res Social Adm Pharm. 2019.  Available online May 12, 2019.
    Abstract
  5. Desselle S, Amin M, Aslani P,  Chen A, Dawoud D, Miller M, Norgaard L. “Moving the needle—what does RSAP look for and what does it aim to do?” Res Social Adm Pharm. 2019 Jan;15(1):1-2. 2018.10.026. Epub 2018 Oct 22.
    Abstract
  6. Miller M, Nutbeam D. “Advancing the international understanding of health literacy in pharmacy: Current trend and future directions.” Res Social Admin Pharm. 2018;14:v-vi.
    Abstract
  7. Danila M, Outman R, Rahn E, Mudano A, Redden D, Li P, Allison J,  Anderson F, Wyman A, Greenspan S, LaCroix A, Nieves J, Silverman S, Siris E, Watts N, Miller M, Curtis J, Warriner A, Wright N, Saag K. “Evaluation of a Multi-modal, Direct-to-Patient Educational Intervention Targeting Barriers to Osteoporosis: A Randomized Clinical Trial.” J Bone Miner Res. 2018;33(5):763–772.
    Abstract
  8. Stirratt M, Curtis J, Danila M, Hansen R, Miller M, Gakumo C. “Advancing the Science and Practice of Medication Adherence. “J Gen Intern Med.  2018;33:216-222.
    Abstract
  9. Bulkley C, Miller M, Draugalis J, Nussbaum B, Bush C. “Preparing Advanced Practice Pharmacists for Research: Needs Assessment and Training Program Development.” Am J Health-Syst Pharm. 2017;74 (23):1986-1995.
    Abstract
  10. Van Den Bogert C, Miller M, Cobaugh D, Chen L, Allison J, Saag K. “Screening questions for nonsteroidal anti-inflammatory drug risk knowledge.” J Patient Saf. 2017;13(4):217-222. doi: 10.1097/PTS.0000000000000143
  11. David C, O’Neal K, Miller M, Johnson J, Lloyd A. “A literacy-sensitive approach to improving antibiotic understanding in a community-based setting.” Int J Pharm Pract. 2017;25(5):395-398. doi:10.1111/ijpp.12332.
  12. Thiessen K, Lloyd A, Miller M, Homco, J, O’Neal K, Gildon B. “Infection. Assessing guideline-concordant prescribing for community-acquired pneumonia.” Int J Clin Pharm. 2017;39(4):674–678. doi: 10.1007/s11096-017-0489-4.
  13. Weech-Maldonado R, Miller M, Lord J. “The Relationships among Socio-Demographics, Perceived Health, and Happiness.” Applied Research in Quality of Life. 2017;12(2):289-302. doi 10.1007/s11482-017-9517-8.
  14. Miller M, Burns C, Kapusnik-Uner J, Carreno R, Matuszewski K. “Depression Screening for Medications with Mental Health Risk. Depression Screening for Prescribed Medications with Mental Health Risk: Considerations for Clinical Decision Support, Workflow Redesign, and Health Information Exchange Arrangements.” Res Social Adm Pharm. 2017;13(3):485-493.
    Abstract
  15. Bulkley C, Miller M, Draugalis J. “Developing and improving residency research training.” Am J Health-Syst Pharm. 2017;74:152-61. DOI: 10.2146/ajhp150797.
  16. Houser S, Au D, Miller M, Chen L, Outman R, Ray M, Saag K, Weech-Maldonado R. “Socio-Demographic Differences in Risk Information Seeking Sources for Non-Steroidal Anti-inflammatory Drugs (NSAIDS).”  International Journal of Medical Informatics. 2016; 94:222-227
    Abstract
  17. Miller M, Weech-Maldonado R, Outman R, Ray M, Gary L, Chen L, Cobaugh D, Allison J, Saag K. “Evaluating the Effectiveness of a Patient Storytelling DVD Intervention to Encourage Physician-Patient Communication About Nonsteroidal Anti-Inflammatory Drug (NSAID) Use.” Patient Educ Couns. 6/16/2016.
    Abstract
  18. Danila M, Outman R, Rahn E, Mudano A, Thomas T, Redden D, Allison J, Anderson F, Anderson J, Cram P, Curtis J, Fraenkel L, Greenspan S, LaCroix A, Majumdar S, Miller M, Nieves J, Safford M, Silverman S, Siris E, Solomon D, Warriner A, Watts N, Yood R, Saag K. “A Multi-Modal Intervention for Activating Patients at Risk for Osteoporosis (APROPROS): Rationale, Design, and Uptake of Online Study Intervention Material.” Contemporary Clinical Trials Communications. 2016; 4: 14-24.
    Abstract
  19. Capino A, Miller J, Hughes K, Miller M, Johnson P. “Caregiver perception, self-efficacy, and knowledge of methadone tapers for children with iatrogenic opioid abstinence syndrome.” J Pharm Technol. 2015; 1-12. DOI: 10.1177/8755122515622030 [original research].
  20. Downes J, O’Neal K, Miller M, Johnson J, Gildon B, Weisz M. “Identifying opportunities to improve medication management in transitions of care.” Am J Health Syst Pharm. 2015; 72(17 Suppl 2):S58-69.
  21. Mittal M, Harrison D, Thompson D, Miller M, Farmer K, Ng Y. “An Evaluation of Three Statistical Estimation Methods for Assessing Health Policy Effects on Prescription Drug Claims.” Res Social Adm Pharm. Published online 4/3/2015. doi:10.1016/j.sapharm.2015.03.004.
  22. Cobaugh D, Miller M, Pham T, Krenzelok E. “Risk of Major Morbidity and Death in Older Adults with Suicidal Intent: A Cross –Sectional Analysis from the National Poison Data System, 2000-2009.” J Am Geriatr Soc. 2015;63:501-507.
  23. Kim M, Lloyd A, Condren M, Miller M. “Beyond Antibiotic Selection: Concordance with the IDSA Guidelines for Uncomplicated Urinary Tract Infections.” Infection. Published online 7/18/2014. DOI 10.1007/s15010-014-0659-4.
  24. Miller M, Allison J, Cobaugh D, Ray M, Saag K. “A Group Randomized Trial of Shared Decision-Making for Nonsteroidal Antiinflammatory Drug Risk Awareness: Primary Results and Lessons Learned.” J Eval Clin Pract. Published online 6/11/2014.
    Abstract
  25. Mittal M, Harrison D, Miller M, Farmer K, Thompson D, Ng Y. “Have antiepileptic drug prescription claims changed following the FDA suicidality warning? An evaluation in a state Medicaid program.” Epilepsy Behav. 2014;34:109-115.
  26. Schupbach R, Sparrow N, Harrison D, Miller M. “Participant Perspectives from the Indian Health Service Anticoagulation Training Program.” Int J Clin Pharm. 2013;35:1091-8.
  27. Mittal M, Harrison D, Miller M, Brahm N. “National Antidepressant Prescribing in Children and Adolescents with Mental Health Disorders after a FDA Boxed Warning.” Res Social Adm Pharm. Published online 20 November 2013.
    Abstract
  28. Winchester B, Watkins S, Brahm N, Harrison D, Miller M. “Mental Health Treatment Associated with Community-Based Depression Screening: Considerations for Planning Multidisciplinary Collaborative Care.” Ann Pharmacother. 2013;47:797-804.
  29. Pham T, Miller M, Harrison D, Lloyd A, Crosby K, Johnson J. “Cardiovascular Disease and Nonsteroidal Anti-inflammatory Drug Prescribing In the Midst of Evolving Guidelines.” J Eval Clin Pract. 2013;19:1026-1034.
  30. Schupbach R, Bousum J, Miller M. “Demonstration of Anticoagulation Patient Self-testing Feasibility at an Indian Health Service Facility: A Case Series Analysis.” Pharmacy Practice. 2013; 11(1): 30-37.
  31. Miller M. “Pharmacy efforts in support of the National Action Plan to Improve Health Literacy.” Res Social Adm Pharm. 2013;9:497.
  32. O’Neal K, Crosby K, Miller M, Murray K, Condren M. “Assessing health literacy practices in a community pharmacy environment: Experiences using the AHRQ Pharmacy Health Literacy Assessment Tool.” Res Social Adm Pharm. 2013;9:564-596.
  33. Collum J, Marcy T, Stevens E, Burns C, Miller M. “Exploring patient expectations for pharmacist-provided literacy-sensitive communication.” Res Social Adm Pharm.  2013;9:626-632.
  34. Wang L, Miller M, Schmitt M, Wen F. “Assessing readability formula differences with written health information materials: application, results, and recommendations.” Res Social Adm Pharm. 2013;9:503-516.
  35. Schmitt M, Miller M, Harrison D, Farmer K, Allison J, Cobaugh D, Saag K. “Communicating Non-Steroidal Anti-Inflammatory Drug Risks: Verbal Counseling, Written Medicine Information, and Patients’ Risk Awareness.” Patient Educ Couns. 2011; 83:391-397.
  36. Miller M, Abrams M, Earles B, Phillips K, McCleeary E. “Improving Patient-Provider Communication for Patients Having Surgery: Patient Perceptions of a Revised Health Literacy-Based Consent Process.” J Patient Saf. 2011;7:30-38.
  37. Rovers J, Miller M, Koenigsfeld C, Haack S, Hegge K, McCleeary E. “A guided interview process to improve student pharmacists’ identification of drug therapy problems.” Am J Pharm Educ. 2011;75(1) Article 16.
  38. Harrison D, Miller M, Schmitt M, Touchet B. “Variations in the Probability of Depression Screening at Community-Based Physician Practice Visits.” Prim Care Companion J Clin Psychiatry. 2010;12(5):e1-e8.
  39. Schmitt M, Miller M, Harrison D, Touchet B. “Relationship of Depression Screening to Physician Office Visit Duration in a National Sample.” Psychiatr Serv. 2010; 61:1126–1131.
  40. Miller M, Allison J, Schmitt M, Ray M, Funkhouser E, Cobaugh D, Saag K, LaCivita C. “Using Single-item Health Literacy Screening Questions to Identify Patients Who Read Written Non-steroidal Anti-Inflammatory Medicine Information Provided at Pharmacies.” J Health Commun. 2010;15:413-427.
  41. Miller M, Schmitt M, Allison J, Cobaugh D, Ray M, Saag K. “The Role of Health Literacy and Written Medicine Information in Non-Steroidal Anti-inflammatory Drug (NSAID) Risk Awareness.” Ann Pharmacother. 2010;44:274-284.
  42. Angner E, Miller M, Ray M, Saag K, Allison J. “Health Literacy and Happiness: A Community-Based Study.” Soc Indic Res. 2010; 95:325–338
  43. LaCivita C, Funkhouser E, Miller M, Ray M, Saag K, Kiefe C, Cobaugh D, Allison J. “Patient Reported Communications with Pharmacy Staff at Community Pharmacies: The Alabama NSAID Patient Safety Study, 2005-2007.” J Am Pharm Assoc. 2009;49:e110–e117. doi: 10.1331/JAPhA.2009.09005.
  44. Miller M, DeWitt J, McCleeary E, O’Keefe K. “Application of the Cloze Procedure to Evaluate Comprehension and to Demonstrate Rewriting of Pharmacy Educational Materials.” Ann Pharmacother. 2009;43:650-657.
  45. Miller M, Abrams M, McClintock B, Cantrell M, Dossett C, McCleeary E, McGee M, O’Keefe K, Sager E. “Promoting Health Communication Between the Community-Dwelling Well-Elderly and Pharmacists: The Ask Me 3 Program.” J Am Pharm Assoc. 2008; 48:784-792
  46. Wall G, Krypel L, Miller M, Rees D. “A Pilot Study of Complementary and Alternative Medicine Use in Patients with Fibromyalgia Syndrome.” Pharmacy Practice. 2007(5(4):185-190.
  47. Miller M, Degenholtz H, Gazmararian J, Lin C, Ricci E, Sereika S. “Identifying Elderly at Greatest Risk of Inadequate Health Literacy: A Predictive Model for Population Health Decision-makers.” Res Social Adm Pharm. 2007; 3(1):70-85.
  48. Gazmararian J, Kripalani S, Miller M, Echt K, Ren J, Rask K. “Factors Associated with Medication Refill Adherence in Cardiovascular-related Diseases: A Focus on Health Literacy.” J Gen Intern Med. 2006; 21:1215-1221.
  49. Degenholtz H, Miller M, Kane R, Cutler L, Kane R. “Developing a Typology of Nursing Home Environments.” J Hous Elderly. 2006; 20(1/2):5-30
  50. Cutler L, Kane R, Degenholtz H, Miller M, Grant L. “Assessing and Comparing Physical Environments for Nursing Home Residents: Using New Tools for Greater Research Specificity.” Gerontologist. 2006; 46(1):42-51.
  51. Miller M, Desselle S. “Employee Knowledge of a Managed Pharmacy Benefit in a Large Employer.” Manag Care Interface. 2005; 18(1):33-42.
  52. Degenholtz H, Thomas S, Miller M. “Race and the intensive care unit: Disparities and Preferences for End of Life Care.” Crit Care Med. 2003; 31(5, Supplement):S373-S378.
  53. Erstad B, Camamo J, Miller M, Webber A, Fortune J.  “Impacting Cost and Appropriateness of Stress Ulcer Prophylaxis at a University Medical Center.”  Crit Care Med. 1997; 25(10):1678-1684.
  54. Miller M, Draugalis J, Ortmeier B, Leischow S.  “A Retrospective Analysis of the Costs and Consequences of a Tobacco Cessation Program for Active Duty Service Members.”  Mil Med. 1996; 161; 7:420-424.
  55. Miller M, Ortmeier B.  “Factors Influencing the Delivery of Pharmacy Services.”  Am Pharm. 1994; NS35; 1:39-45.
  1. Barriers and Facilitators to Provider Adoption of Medication Price Transparency Tools in Electronic Medical Records: A Qualitative Study
    Goal:
    The objective of this study is to characterize the utility of these separate medication transparency tools and to elicit provider perceptions on their comparative value of these tools for practice management, for specifically improving patient-provider communication and for patient-medication treatment adherence
    Funder:
    JHU/KP Collaboration on Learning Healthcare Organizations
    Role: Co-Investigator
  2. Use of Path Modeling to Inform a Clinical Decision Support Application to Encourage Osteoporosis Treatment Initiation
    Goal:
    This study aimed to evaluate the interrelationship of patient sociodemographic factors, perceived fracture risk, health literacy, receipt of medication information, medication trust and patient readiness to use osteoporosis medication in older US women at risk for future fractures to inform the content of a practical application for personalized patient counseling that can be easily integrated into clinical decision support systems.
    Funder:
    This research was funded, in part, by NIAMS/NIH R01 AR060240 and NIAMS/NIH K23 AR062100. This funding occurred prior to me joining KP.
    Role: Co-Investigator
  3. Development, Deployment, and Evaluation of a Pharmacist-Coordinated Appointment-Based Model for Medication
    Goal:
     This objective of this study is to… test.
    Funder:
    This project is not yet funded. It is under review with Pfizer, Inc.
    Role: Principal Investigator